Table 4.
Overall survival of patients with surgically treated NSCLC according to analysed variables.
| Variable | OS (Months) | SE | 95% CI | Median | LR | p |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Males | 46 | 3.9 | 38–53 | 44 | 1.65 | 0.199 |
| Females | 50 | 5 | 41–60 | |||
| Histologic type | ||||||
| ADC | 49.8 | 3.9 | 42.2–57.5 | 62 | 2.14 | 0.143 |
| SCC | 42.4 | 5.6 | 31.4–53.5 | 38 | ||
| Adenocarcinoma subtype | ||||||
| Acinar | 59 | 4.6 | 50–68 | 68 | ||
| Papillary | 43.5 | 7.8 | 28–59 | 37 | 4.5 | 0.009 |
| Solid | 24.8 | 3 | 18.9–31 | 27 | ||
| Histological gradus | ||||||
| 1 | 51 | 6.6 | 38–64 | 62 | 1.07 | 0.585 |
| 2 | 47.2 | 4.2 | 39–55 | 48 | ||
| 3 | 45.2 | 6.6 | 32–58 | 34 | ||
| Lympho-vascular invasion | ||||||
| No | 58 | 5 | 48–68 | 68 | 6.3 | 0.012 |
| Yes | 38.8 | 4 | 31–47 | 37 | ||
| Pathological stage | ||||||
| 1 | 52.4 | 4.4 | 44–61 | 62 | 2.99 | 0.224 |
| 2 | 44 | 6 | 33–56 | 38 | ||
| 3 | 38 | 5.5 | 27–49 | 37 | ||
| Lymph node status | ||||||
| Negative | 51 | 4 | 42–59 | 53 | 1.4 | 0.235 |
| Positive | 41 | 5 | 31–51 | 37 | ||
| PD-L1 | ||||||
| Negative | 47.9 | 4.5 | 39–57 | 44 | 0.15 | 0.643 |
| Positive | 47 | 4.7 | 38–56 | 48 | ||
| IMR | ||||||
| Absent | 43.5 | 4.7 | 34–53 | 37 | 2.8 | 0.246 |
| Low | 46 | 5 | 36–56 | 49 | ||
| Strong | 58 | 6 | 45–71 |
Log rank test. IMR immune microenvironment response.